8-K: Recursion Pharmaceuticals Expands Board with Appointments of Elaine Sun and Dr. Namandj Bumpus

Recursion Pharmaceuticals appoints Elaine Sun and Dr. Namandj Bumpus to its Board of Directors, effective March 15, 2025, to bolster its leadership team.

Summary

• Recursion Pharmaceuticals has expanded its Board of Directors by appointing Elaine Sun and Dr. Namandj Bumpus, effective March 15, 2025.
• The Board increased its size from 8 to 10 members to accommodate the new appointments.
• Elaine Sun has been appointed as a Class III Director with a term extending until the 2027 Annual Meeting of Stockholders and will serve as the Chair of the Audit Committee and a member of the Compensation Committee.
• Dr. Namandj Bumpus has been appointed as a Class III Director with a term extending until the 2027 Annual Meeting of Stockholders and will serve as a member of the Nominating Committee, the Research and Development Committee, and the Technology Committee.
• Both Ms. Sun and Dr. Bumpus will receive cash and equity compensation as per the company's Outside Director Compensation Policy.
• The Board also established two new committees: the Research and Development Committee and the Technology Committee.
• The Director Compensation Policy was amended to include compensation terms for members of these new committees.
• The annual cash retainer for outside directors is $35,000.
• Additional annual cash retainers are provided for committee chairs and members, ranging from $5,000 to $30,000 depending on the committee and role.
• Outside Directors can elect to receive fully vested shares in lieu of their annual cash retainer.
• Initial equity awards for new outside directors include options and restricted stock units, each with a grant date fair value of $250,000.
• Annual equity awards for outside directors include options and restricted stock units, each with a grant value of $112,500.
• No outside director may be paid, issued or granted, in any Fiscal Year, cash compensation and equity compensation with an aggregate value greater than $850,000 for an Outside Director's first year of service or $600,000 in any subsequent year.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the addition of experienced board members and the expansion of board committees, indicating a strengthening of the company's leadership and strategic focus.

Positives

• The addition of Elaine Sun and Dr. Namandj Bumpus brings significant expertise in finance, operations, regulatory strategy, and scientific innovation to Recursion's Board.
• The establishment of the Research and Development and Technology Committees demonstrates a commitment to innovation and technological advancement.
• The Outside Director Compensation Policy provides a structured approach to attracting and retaining qualified board members.
• The option for directors to receive fully vested shares in lieu of cash retainers aligns their interests with those of shareholders.
• The company is expanding its leadership team at an exciting time for Recursion.

Future Outlook

The company anticipates that the new board members' expertise will support its continued success as it grows its clinical pipeline and enhances its platform.

Management Comments

• Chris Gibson, Ph.D., Recursion Co-Founder and CEO, stated that the new board members' scientific, clinical, business and financial expertise will be an incredible resource in support of the company's continued success.
• Dr. Bumpus looks forward to bringing her experience as a scientist and leader to help guide the company's scientific approach and advance its impact on patients' lives.
• Elaine Sun is excited to support Recursion's commitment to merging rigorous science with cutting-edge technology to accelerate drug discovery and development and reshape the industry.
• Rob Hershberg, MD/Ph.D., Recursion's Chairman, expressed his delight in having such phenomenal additions to the Board at such an exciting time for Recursion.

Industry Context

The appointment of experienced leaders from the FDA and the biotech industry reflects a strategic move to strengthen Recursion's position in the competitive TechBio landscape. The company is investing in expertise across regulatory affairs, finance, and scientific innovation to support its growth and development of new therapies.

Comparison to Industry Standards

• The compensation structure for Recursion's outside directors, including cash retainers and equity awards, appears to be in line with industry standards for publicly traded biotechnology companies.
• Companies like Halozyme Therapeutics and Dynavax Technologies, where Elaine Sun previously held leadership roles or currently serves on the board, provide a benchmark for compensation and governance practices.
• The establishment of specialized committees such as the Research and Development and Technology Committees is a common practice among innovative companies seeking to leverage expertise in specific areas.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may view the board expansion and committee enhancements positively, as they indicate a commitment to strong governance and strategic oversight.
• Employees may benefit from the expertise and guidance of the new board members, particularly in the areas of research and development and technology.
• The company's ability to attract and retain top talent may be enhanced by the presence of experienced and respected board members.

Next Steps

• Ms. Sun and Dr. Bumpus will assume their roles on the Board and participate in relevant committee activities.
• The company will continue to implement its Outside Director Compensation Policy.
• The Board will continue to oversee the company's strategic direction and operations.

Key Dates